Exeltis is an organization committed to innovation, excellence and healthcare. Our aim is to become a point of reference in the pharmaceutical sector.
Exeltis is the result of the natural evolution and sustained growth of the CHEMO pharmaceutical business, an integrated health sciences group. It combines the Group’s know-how and experience with the innovative spirit of Exeltis, becoming a global organization with the capacity to discover, develop, produce and market medicinal products and medical devices that can help to improve the quality of life of millions of people worldwide.
People are our core concern and guiding force. In order to provide better therapeutic solutions and reach more people worldwide, Exeltis has taken its operations to every continent, giving even more patients rapid and effective access to our wide range of products.
With our innovative spirit, we use all our know-how, resources and human capital to develop solutions that meet patients’ unsatisfied needs. Our endeavour to find new therapeutic alternatives had led us to join forces with other leading pharmaceutical companies that share our enthusiasm and to establish alliances in order to progress together in healthcare.
Our main mission is twofold:
“Exeltis is an exaltation of excellence, innovation and diversity”
Our philosophy, character and work ethos are captured in our emblem “Rethinking Healthcare”
The CHEMO Group start up branded pharmaceutical business in Europe after acquiring 50% of EFFIK, a specialist company in gynaecology.
Strategic alliances open the door to Asia through Sinensix Pharma (Tailand, Vietnam), to Russia and CIS countries with the new BC Pharma subsidiary and to Mexico thanks to Elea Mexico.
Growth continues in Asia with Chemo Wanbang Biopharma and Chemway.
Agreement to market a novel, unique treatment for diabetic foot.
The company increases its production capacity in America by joining the US market through Everett Labs and the new group members, Altian Pharma (Central America), VyT Pharma (Paraguay), Everett (USA).
Its presence in Europe expands to the largest market, Germany, through Velvian, as well as to Poland and Eastern Europe, where it was already present with TemaPharm y Ladee Pharma, respectively.
Consolidation of South-East Asian market with Nufarindo (Indonesia) and Exeltis Malaysia, start of operations in India with a new partner, Ordain, and the addition of Austria and Switzerland to the European market with Velvian and Veldana, respectively. Its American operations are strengthened with Eticos (Paraguay).
Creation of the Ladee Pharma Research Institute (LPRI), engaged in developing new products, primarily in the Women's Health sector.
The company arrives in Africa with the acquisition of Althéa Pharma, specifically in the Moroccan market, with special emphasis on Women's Health, in which we are a company of reference.
Evolution and sustained growth in the branded pharmaceuticals market leads to the creation of Exeltis.
Exeltis consolidates its presence in the United States. It has acquired 100% of Quinnova Pharmaceuticals, a US company specializing in a wide variety of dermatological products.
Exeltis has acquired 100% of the Turkish pharmaceutical Embil. The deal is the biggest acquisition ever by Exeltis abroad. The deal is part of Exeltis's Strategic Plan that aims to consolidate its international development.
“Excellence, respect, responsibility and integrity are our values”
We work hard to meet our commitments on a daily basis. All our efforts, resources and human capital are people-oriented and focussed on developing medicinal products that can help improve human health.
In our endeavour to provide health solutions and make our products more readily and easily accessible, we establish alliances that enable us to operate worldwide.
Aware of the significant impact our activities have on people’s quality of life, we do not simply provide medical solutions – we make sure that all our products meet the highest standards of quality and safety.
All our processes are held to strict standards and comply with current international legislation and guidelines, in addition to our own quality and safety policies.
We aim to achieve sustainable development, and to do so we carefully assess our environmental footprint and protect and improve our environment.
Exeltis is committed to protecting the environment, and we are constantly improving our processes, products and services to this end. We endeavour to minimise the impact of our production activities, facilities and offices worldwide, to guarantee effective waste management and efficient use of resources and to promote ecological habits throughout the organisational chain.
Through Mundo Sano Foundation, Exeltis works to reduce the impact of Neglected Tropical Diseases (NTDs) such as Chagas disease and Dengue fever by researching, preventing and treating these conditions which affect billions of people worldwide, particularly in developing countries.
Mundo Sano is part of a global alliance, led by the Bill & Melinda Gates Foundation, which aims to promote cooperation for the immediate control or eradication of 10 Neglected Tropical Diseases (NTDs). It supports the objectives established by the World Health Organization (WHO) and the United Nations Millennium Development Goals (MDGs) for 2020.
Then you have to visit the website Mundo Sano.